TP53 and hepatocellular carcinoma: We further compared side-by-side the survival benefit of the combination of CTCE-p53 NPs with aPD1 against a regimen similar to the new standard of care in HCC patients (i.e., anti-VEGFR2 antibody+ aPD-L1 antibody) in the orthotopic RIL-175 tumor model (Supplementary Fig. 20).